Shingles vaccine reduces risk by 55%, but uptake still low in the US
This article was originally published in Scrip
Executive Summary
A Kaiser Permanente study on US community real-world use has shown that a one-shot herpes zoster vaccine (Merck & Co's Zostavax) was associated with a 55% reduced risk of developing shingles in people aged over 60 years, reinforcing results from a previous clinical trial of the drug.